A class of compounds selectively inhibiting PTP1B and preparation method and application thereof

By extracting arastin-type anthraquinone glycoside compounds from red euphorbia, a new allosteric inhibitor with selective inhibition of PTP1B activity was developed, which solved the problem of poor selectivity of existing PTP1B inhibitors, and achieved type 2 diabetes and Effective treatment of obesity.

CN115403640BActive Publication Date: 2024-11-01BINZHOU MEDICAL COLLEGE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211075556.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-05
Publication Date
2024-11-01
Estimated Expiration
2042-09-05

AI Technical Summary

Technical Problem

The existing PTP1B inhibitors have poor selectivity, obvious side effects on the inhibitory effect of TCPTP, lack of allosteric inhibitors with high selectivity and low bioavailability, making it difficult to effectively treat type 2 diabetes and obesity.

Method used

Amarini anthraquinone glycoside compounds were extracted and synthesized from the red euphorbia. Through specific structural design and preparation methods, anthraquinone glycoside compounds that selectively inhibit PTP1B activity were developed, and their allosteric sites of PTP1B were used. Targeted to prepare highly selective and low side effects PTP1B inhibitors.

Benefits of technology

The compounds have strong inhibitory effects on PTP1B and weak effects on TCPTP. They significantly improve the selectivity of PTP1B inhibitors, can reverse insulin resistance, and provide new drug candidates for the treatment of type 2 diabetes and obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115403640B_ABST
    Figure CN115403640B_ABST
Patent Text Reader

Abstract

The present invention relates to a class of compounds with selective inhibition of protein tyrosine phosphatase 1B (PTP1B), and the compounds are new compounds with an anthraquinone glycoside mother nucleus. The present invention also provides a preparation method and application of the compounds. The compounds can specifically inhibit the activity of PTP1B, and the selectivity between PTP1B and its family T-cell protein tyrosine phosphatase (TCPTP) is up to 74 times. The compounds can significantly increase the sensitivity of cells to insulin, and have good application prospects in the preparation of hypoglycemic drugs specifically targeting PTP1B, and drugs for the treatment of type 2 diabetes and / or obesity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a new anthraquinone glycoside compound derived from natural medicines and having the ability to selectively inhibit PTP1B activity, as well as a preparation method and use thereof. Background Art

[0002] Diabetes has become one of the most important non-communicable diseases threatening human health worldwide. According to statistics from the International Diabetes Federation (IDF), the number of diabetes patients in the world reached 370 million in 2011, 80% of whom were in developing countries. It is estimated that there will be nearly 550 million diabetes patients in the world by 2030. Among the patients in my country, type 2 diabetes (non-insulin-dependent) is the main type, accounting for more than 90%. The chronic hyperglycemia caused by it and the various chronic complications such as retinopathy, chronic kidney disease, neuropathy, and hypertension not only bring physical and mental damage to patients, but also bring heavy economic burdens to individuals and the country. Therefore, the research and development of hypoglycemic drugs is of great significance to the healthy development of my country's society and economy.

[0003] Protein tyrosine phosphatase 1B (PTP1B) is a subtype of the protein tyrosine phosphatase (PTP) family. It was first isolated from human placental tissue and is widely distributed in tissues such as the liver, kidney and placenta. PTP1B is closely related to insulin resistance and obesity. It plays a negative regulatory role in the insulin and leptin signaling pathways. It promotes insulin receptor dephosphorylation, downregulates insulin and leptin levels, causes the body to tolerate insulin, and causes hyperglycemia and obesity. Therefore, PTP1B is an effective target for the treatment of type 2 diabetes and obesity. However, the catalytic active sites of the protein tyrosine phosphatase family are highly conserved, and PTP1B inhibitors designed for the catalytic site have poor selectivity and obvious side effects. Among them, T-cell protein tyrosine phosphatase (TCPTP) has the highest homology with PTP1B. The amino acid sequences of the catalytic regions of the two are nearly 80% identical, but the physiological function of TCPTP is different from that of PTP1B. In particular, studies have shown that TCPTP gene knockout mice have a high mortality rate, and cross-inhibition of TCPTP may cause serious side effects. Therefore, a large number of studies have been devoted to finding drugs that can effectively inhibit PTP1B but have low inhibitory effects on TCPTP. In recent years, several allosteric sites of PTP1B have been reported, such as the allosteric site composed of α3 and α6 helices, and the allosteric site located in the α9′ helix of the C-terminal part. They are far away from the active site and have the characteristics of lipophilicity and low homology. Inhibitors targeting this type of site have the advantages of high selectivity and good bioavailability, especially weak effects on TCPTP, and better drugability. However, there are very few reports on inhibitors targeting this type of allosteric site.

[0004] In recent years, the inventors have been committed to finding PTP1B allosteric inhibitors from natural medicines to solve technical deficiencies such as poor selectivity of PTP1B inhibitors and lack of new allosteric inhibitors. The inventors discovered a series of new anthraquinone glycoside compounds from the traditional Chinese medicine Knoxia valerianoides, which are glycoside compounds formed by the combination of alizarin-type anthraquinone and glucose or primulose. The anthraquinone part has a special structure, and the A / B benzene rings on both sides of the structure are substituted with hydroxyl or methoxy groups. Molecular docking experiments show that the hydroxyl and / or methoxy groups of the A / B rings have an important contribution to improving the PTP1B inhibitory activity. The new anthraquinone glycoside compounds involved in the present invention are a new type of PTP1B allosteric inhibitor. At present, there is no report on anthraquinone glycoside compounds having PTP1B allosteric inhibitory effect or selective inhibition of PTP1B activity. The anthraquinone glycoside compounds of the present invention have a strong inhibitory effect on PTP1B and a very weak effect on TCPTP, showing high selectivity; they can reverse the glucose uptake efficiency of insulin-resistant skeletal muscle C2C12 cells; and can be used to prepare selective PTP1B inhibitors and develop drugs for the treatment of type 2 diabetes and / or obesity with high specificity and low side effects. Summary of the invention

[0005] In order to solve the shortcomings of existing PTP1B inhibitors, one of the purposes of the present invention is to provide a new class of compounds with selective inhibition of PTP1B activity, having an anthraquinone glycoside compound shown in Formula I or Formula II or a pharmaceutically acceptable salt, ester, stereoisomer, solvent compound thereof,

[0006]

[0007] Wherein, R1, R2, R3, and R4 are independently selected from H, OH, OCH3, CH2OH or xylosyl.

[0008] The anthraquinone glycoside compound represented by formula I or formula II is preferably:

[0009]

[0010] The second object of the present invention is to provide a method for preparing the compound, comprising the following steps:

[0011] (1) Extraction and separation: The red euphorbia was crushed, extracted with ethanol as solvent, filtered to obtain the extract, and concentrated to obtain the extract. The extract was dissolved in water, and the aqueous solution after extraction with ethyl acetate was separated by macroporous adsorption resin column chromatography, and then separated by MCI column chromatography to obtain the target compound-containing parts KVB, KVC, KVD and KVE.

[0012] (2) Purification: The target compound-containing fractions KVB, KVC, KVD and KVE obtained in step (1) are first purified by preparative HPLC and then by semi-preparative HPLC to obtain target compounds KV-1 to KV-9.

[0013] Preferably, in step (1), the ethanol concentration of the extraction method is 90%, and the extraction temperature is room temperature. In the macroporous adsorption resin column chromatography method, the mobile phase is ethanol / water, and the concentration is 0% to 95%. In the MCI column chromatography method, the stationary phase is MCI gelCHP20p, and the mobile phase is methanol / water, and the concentration is 40% to 90%.

[0014] Preferably, in step (2), in the HPLC method, the stationary phase of the chromatographic column is ODS; in the preparative HPLC method, the mobile phase is 40% to 80% methanol / water; in the semi-preparative HPLC method, the mobile phase is 30% to 50% acetonitrile / water or 45% to 65% methanol / water.

[0015] More preferably, in step (2), part KVB is purified by preparative HPLC, 53% methanol / water, and then by semi-preparative HPLC, 30% acetonitrile / water to obtain compound KV-9 of the present invention, and is purified by semi-preparative HPLC, 49% methanol / water to obtain compound KV-1 of the present invention. Part KVC is first purified by preparative HPLC, 55% methanol / water, and then by semi-preparative HPLC, 50% to 57% methanol / water to obtain compounds KV-4, KV-5, KV-6 and KV-7 of the present invention. Part KVD is first purified by preparative HPLC, 60% methanol / water, and then by semi-preparative HPLC, 56% methanol / water to obtain compounds KV-3 and KV-8 of the present invention. Part KVE is first purified by preparative HPLC, 65% methanol / water, and then by semi-preparative HPLC, 52% methanol / water to obtain compound KV-2 of the present invention.

[0016] The third object of the present invention is to provide the use of such compounds or their pharmaceutically acceptable salts, esters, stereoisomers, solvent compounds in the preparation of selective PTP1B inhibitors, drugs for the treatment of type 2 diabetes and / or drugs for the treatment of obesity.

[0017] The series of compounds of the present invention can be used alone or in combination. If used as a group of compounds, these compounds can be administered to the subject simultaneously, separately or sequentially.

[0018] The series of compounds of the present invention belong to the glycoside compounds formed by alizarin-type anthraquinone and sugar, and each compound has a significant inhibitory effect on PTP1B. Among them, the inhibitory strength of compounds KV-4, KV-7 and KV-8 on PTP1B is 73, 25 and 63 times higher than that on TCPTP, respectively, and they are a class of specific PTP1B inhibitors. Most alizarin-type anthraquinones have no substituents on the A ring, while the alizarin-type anthraquinone A ring of the present invention has hydroxyl and / or methoxy substitutions. Preliminary structure-activity relationship and molecular docking experiments show that the hydroxyl and / or methoxy of the A ring have an important contribution to the activity intensity. Moreover, enzyme inhibition kinetics and molecular docking experiments show that the series of compounds of the present invention are a class of new PTP1B allosteric inhibitors. The structure, selective PTP1B inhibitory activity and mechanism of action on the allosteric site of PTP1B of the compounds involved in the present invention are all reported for the first time, which provides a reference for further research and development of highly specific PTP1B inhibitors, and has broad application prospects in the development of new hypoglycemic drugs, type 2 diabetes treatment drugs and / or obesity treatment drugs targeting PTP1B. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 :The results of enzyme inhibition kinetics experiment of compound KV-4

[0020] Figure 2 :Molecular docking results of compound KV-4

[0021] Figure 3 Effects of compounds KV-1(A), KV-3(B) and KV-8(C) on the changes of glucose uptake in insulin-resistant skeletal muscle C2C12 cells DETAILED DESCRIPTION

[0022] The following is a further description of the compounds, preparation steps and activity screening experimental process of the present invention through specific examples. The following examples are used to illustrate the technical content of the present invention and are not intended to limit the content of the present invention. All changes or equivalent substitutions made based on the present invention should fall within the scope of protection of the present invention.

[0023] Example 1 Preparation of Compounds KV-1 to KV-9

[0024] 20 kg of red euphorbia was crushed and ultrasonically extracted with 95% ethanol at room temperature. The extract was combined with the solvent and evaporated under reduced pressure to obtain 3.9 kg of extract. After the extract was dissolved in water, it was extracted with ethyl acetate three times. The remaining aqueous solution was fully adsorbed with macroporous adsorption resin, and then eluted with 0%, 30%, 50%, 70% and 95% ethanol / water in sequence. The 70% ethanol / water elution part was then separated by MCI column chromatography and eluted with 40% to 90% methanol / water to obtain 6 parts (KVA, KVB, KVC, KVD, KVE and KVF). Part KVB was purified by preparative high-performance liquid chromatography, and 53% methanol / water was used to obtain parts KVB-1, KVB-4 and KVB-5. Part KVB-1 was purified by semi-preparative high-performance liquid chromatography, and 30% acetonitrile / water was used to obtain compound KV-9. Parts KVB-4 and KVB-5 were purified by semi-preparative HPLC, eluted with 49% methanol / water to obtain compound KV-1. Part KVC was purified by preparative HPLC, eluted with 55% methanol / water to obtain parts KVB-2, KVB-3 and KVB-4. KVB-2 was purified by semi-preparative HPLC, eluted with 57% methanol / water to obtain compounds KV-6 and KV-7. KVB-3 and KVB-4 were purified by semi-preparative HPLC, eluted with 50% methanol / water to obtain compounds KV-4 and KV-5. Part KVD was first purified by preparative HPLC, eluted with 60% methanol / water, and then purified by semi-preparative HPLC, eluted with 56% methanol / water to obtain compounds KV-3 and KV-8. Part KVD was first purified by preparative HPLC, eluted with 65% methanol / water, and then purified by semi-preparative HPLC, eluted with 52% methanol / water to obtain compound KV-2. The structures of the obtained compounds were determined according to Table 1, Table 2, Table 3 and the following spectral information.

[0025] KV-1:UV(MeOH):λ max (logε)413(4.85),337(3.93),301(4.35),272(4.85),218(4.70)nm; IRν max 3320,2886,1669,1632,1594,1481,1367,1296,1234,1077,1038,1004,922,895,765cm -1 ; HR-ESI-MS m / z 593.1480[MH] - (calcd for C 27 H 29 O 15 ,593.1501).

[0026] KV-2:UV(MeOH)λ max(logε)413(4.19),339(4.05),304(4.40),274(5.00),214(4.81)nm;IRν max 3544,3361,2923,2852,1672,1622,1595,1488,1414,1361,1308,1293,1239,1095,1074,1011,926,780,671cm -1 ;(-)-HRESIMS m / z 577.1519[M-H] - (calcd forC 27 H 29 O 14 ,577.1552).

[0027] KV-3:UV(MeOH)λ max (logε)447(4.08),312(4.01),270(4.58),229(4.50)nm;IRν max 3342,2933,2883,1624,1604,1456,1438,1371,1318,1099,1074,1051,991,949,806,768cm -1 ;(-)-HRESIMS m / z 593.1478[M-H] - (calcd for C 27 H 29 O 15 ,593.1501).

[0028] KV-4:UV(MeOH)λ max (logε)453(3.85),315(4.00),270(4.49),229(4.35)nm;IRν max 3273,2988,2901,1624,1599,1453,1412,1367,1276,1039,1015,892,769cm -1 ;(-)-HRESIMSm / z 579.1324[M-H] - (calcd for C 26 H 27 O 15 ,579.1350)

[0029] KV-5:UV(MeOH)λ max (logε)447(4.05),266(4.57),215(4.83)nm;IRνmax 3545,3306,2901,1625,1589,1484,1456,1421,1367,1263,1100,1080,1049,937,741cm -1 ;(-)-HRESIMS m / z 609.1410[M-H] - (calcd for C 27 H 29 O 16 ,609.1450).

[0030] KV-6:UV(MeOH)λ max (logε)427(4.10),338(4.21),305(4.51),275(4.81),215(4.79)nm;IRν max 3330,2891,1668,1623,1593,1440,1368,1285,1035,1007,931,817cm -1 ;(-)-HRESIMS m / z 593.1468[M-H] - (calcd for C 27 H 29 O 15 ,593.1501).

[0031] KV-7:UV(MeOH)λ max (logε)415(4.03),280(4.60),245(4.66)nm;IRν max 3569,3196,2918,1671,1611,1590,1443,1403,1330,1289,1244,1195,1154,1127,1073,1017,941,904,878,825,762,735,716cm -1 ;(-)-HRESIMS m / z 431.0955[M-H] - (calcd forC 21 H 19 O 10 ,431.0973).

[0032] KV-8:UV(MeOH)λ max (logε)413(4.06),337(3.93),304(4.30),272(4.82),217(4.73)nm;IRν max3319,2897,1665,1632,1593,1479,1446,1371,1330,1233,1095,1070,1027,1008,938,853,769cm -1 ;(-)-HRESIMS m / z 461.1046[MH] - (calcd for C 22 H 21 O 11 ,461.1078).

[0033] KV-9:UV(MeOH)λ max (logε)447(4.06),311(4.02),266(4.51),231(4.54)nm; IRν max 3281,2918,1621,1591,1456,1426,1374,1299,1224,1124,1070,985,940,765,727cm -1 ;(-)-HRESIMS m / z 477.1003[MH] - (calcd for C 22 H 21 O 12 ,477.1028).

[0034] Table 1. H NMR data of compounds KV-1 to KV-5

[0035]

[0036]

[0037] Table 2. H NMR data of compounds KV-6 to KV-9.

[0038]

[0039]

[0040] Table 3. C NMR spectra of compounds KV-1 to KV-9

[0041]

[0042] Example 2 Evaluation of PTP1B and TCPTP Inhibitory Activity

[0043] The compound was prepared into gradient concentrations using DMSO. The pre-prepared enzyme solution (buffer containing 25mM Hepes pH7.5, 150mM NaCl, 5mM DTT, 2mM EDTA, containing 0.1μg PTP1B or 0.15μg TCPTP) was added to a 96-well plate, 90μL per well, and 1μL of compound solution was added to each well. DMSO was used as a blank control, and three parallel wells were set for each concentration. The 96-well plate was placed in a constant temperature oscillator and shaken at 37°C for 15 minutes. After 15 minutes, 10μL of p-NPP solution with a final concentration of 4mM was added, and the plate was shaken at 37°C in a constant temperature oscillator for 30 minutes. After 30 minutes, take it out and add 20μL of 3M NaOH solution in sequence to terminate the reaction. Finally, the OD value was measured at 405nm on an enzyme reader to calculate the inhibition rate and IC of the compound on PTP1B. 50 Sodium vanadate (Na3VO4) was used as the positive control drug.

[0044] Calculation formula: Inhibition rate = (OD 空白 -OD 样品 ) / OD 空白 ×100%

[0045] The above data were statistically analyzed using GraphPad Prism 8.0 software. The experiments were repeated three times and the data were expressed as mean ± standard deviation.

[0046] Table 4. Enzyme inhibitory activity of compounds KV-1 to KV-9

[0047]

[0048] SI is IC 50 (TCPTP) / IC 50 (PTP1B); NT is not tested.

[0049] The data in Table 4 show that compounds KV-1 to KV-9 all show significant PTP1B inhibitory activity. Due to the insufficient amount of some compounds, the inhibitory effect on TCPTP could not be detected. Only the inhibitory effect of compounds KV-1, KV-3, KV-4, KV-7 and KV-8 on TCPTP was detected. The positive control drug Na3VO4 is a classic competitive inhibitor of protein tyrosine phosphatase, which competes with the substrate for the active site of the phosphatase. The data in Table 4 show that Na3VO4 has comparable inhibitory effects on PTP1B and TCPTP and is non-selective. However, KV-1, KV-3, KV-7 and KV-8 still have no significant inhibitory effect on TCPTP at the highest concentration of 100μM, and only KV-4 shows a weak inhibitory effect. The experimental results show that this class of compounds exhibits high selectivity for PTP1B, with the selectivity of KV-4 reaching up to 74 times.

[0050] Example 3 PTP1B enzyme inhibition kinetics experiment

[0051] The pre-prepared PTP1B solution was added to a 96-well plate, 90 μL per well, and 1 μL of KV-4 solution was added, with final concentrations of 1, 2, and 4 μM, respectively. Three replicate wells were set for each concentration, and DMSO was used as a blank control. The 96-well plate was placed in a constant temperature oscillator and shaken at 37°C for 15 minutes. Then p-NPP solution (final concentrations of 2, 4, and 8 mM, respectively) was added, and the OD value change at 405 nm within 15 minutes was immediately measured with an ELISA instrument to calculate the initial rate of enzymolysis. The inhibition type of PTP1B was analyzed by plotting the substrate concentration as one-half and the initial rate of enzymolysis using Lineweaver-Burk plot.

[0052] Figure 1 The results of the kinetic experiment show that each group of curves converges to the xy axis area, indicating that KV-4 is a mixed inhibitor of PTP1B and can bind to other sites outside the catalytic active region of PTP1B, suggesting that it may bind to the allosteric site of PTP1B to exert an inhibitory effect.

[0053] Example 4 Molecular docking

[0054] The C-DOCKER module of the molecular docking software BIOVIA Discovery Studio 2021 was used to perform molecular docking simulations on the active sites and allosteric sites of KV-1~KV-9 and the PTP1B crystal structure. The crystal structure of PTP1B comes from the protein crystal library, numbered 1T49. First, the 3D structure of KV-1~KV-9 was calculated using Discovery Studio 3.0 software to obtain the optimal conformation. After dehydration and hydrogenation, the PTP1B protein structure was optimized using the CHARM force field structure. The optimal conformation of the compound was then docked and calculated with the crystal structure of PTP1B, and the software scored and analyzed the action site and binding mode of the highest-scoring conformation.

[0055] The results showed that compounds KV-1 to KV-9 could not successfully dock with the catalytic active pocket of PTP1B, but could bind well to the allosteric site of PTP1B and stabilize the conformation of the enzyme-inhibitor complex through a series of actions. This result is consistent with the results of enzyme inhibition kinetics experiments. Taking the docking results of compound KV-4 as an example ( Figure 2), KV-4 inserts anthraquinone into the allosteric pocket, forms a strong π-π stacking interaction with Phe196 and Leu192, and forms a hydrogen bond with Asn193 to enhance the binding force, while the sugar in the structure forms hydrogen bonds with Glu276, Gly277 and Lys279, further strengthening the binding strength with the allosteric site. Therefore, the compounds of the present invention are a new type of PTP1B allosteric inhibitors, which can be developed as highly efficient and selective PTP1B inhibitors.

[0056] Example 5 Effects of Compounds on Glucose Consumption in Insulin-Resistant Skeletal Muscle C2C12 Cells

[0057] Cell differentiation: C2C12 mouse myoblasts were cultured to 80% density and subcultured. After culturing a sufficient number of cells, the cells were digested, centrifuged, resuspended, and plated at 2×10 4 Each well was plated with 100 μl of PBS per well and cultured in a cell culture incubator for 12 hours. After the cells adhered to the wall, the supernatant was discarded, 100 μl of PBS was added to each well for three rinses, and 200 μl of fresh differentiation medium was added to each well for another 24 hours. From then on, fresh differentiation medium was replaced every 24 hours for a total of 96 hours of differentiation culture until the single spindle cells were differentiated into regularly arranged multinucleated fused muscle cells.

[0058] Construction of insulin-resistant muscle cell model: aspirate the differentiated muscle cell culture medium, add 100μl PBS to each well to rinse the cells 3 times, add 200μl high-glucose DMEM medium to each well of the normal group cells, add 200μl prepared modeling insulin solution to each well of the model group and drug-added group cells, and place the cells in a cell culture incubator at 37℃ and 5% CO2 for 48h. After 48h, if the cell glucose uptake in the model group is significantly reduced compared with the blank group, it proves that the modeling is successful.

[0059] Administration: The compound was diluted with high-glucose DMEM medium to a final concentration of 50 μM, 33.3 μM, and 22.2 μM, respectively. After aspirating the culture medium in each well, 200 μl of high-glucose DMEM medium was added to each well of the normal group and model group cells, and 200 μl of drugs of each concentration were added to each well of the drug-added group. Three replicate wells were set for each concentration, and the experiment was repeated three times.

[0060] Glucose content detection: Place the cells in the incubator and continue to culture. After 48 hours, prepare the glucose content detection solution according to the operating method in the instructions of the kit. In a new 96-well plate, add 180μl of glucose content detection solution to each well, add 20μl of cell supernatant from each well, and incubate in a constant temperature oscillator at 37°C for 15 minutes. After 15 minutes, measure the OD value of the 96-well plate at 505nm on an enzyme reader, and calculate the glucose content in each well according to the calculation formula in the instructions of the kit. Add 20μl of the pre-prepared MTT solution to the supernatant of the 96-well plate containing cells, culture in a cell incubator for 4 hours, and then measure the OD value at 490nm with an enzyme reader. In order to eliminate the influence of cell number on the test results, the glucose content / MTT value is used as the final glucose content.

[0061] Figure 3 The figure shows the changes in glucose consumption of insulin-resistant skeletal muscle C2C12 cells under different concentrations of KV-1, KV-3 and KV-8. Compared with the normal group, the glucose consumption of cells in the model group was significantly reduced, while the glucose consumption of cells in the drug-treated group was significantly increased, and there was a dose-effect relationship. This shows that KV-1, KV-3 and KV-8 can reverse the low sensitivity of skeletal cells to insulin, improve the response of skeletal muscle cells to insulin, and thus increase the uptake and consumption of glucose. Therefore, this type of anthraquinone glycoside compound is expected to be developed into a new type of hypoglycemic drug, a drug for the treatment of type 2 diabetes and / or obesity.

Claims

1. A compound or a pharmaceutically acceptable salt thereof for selectively inhibiting PTP1B, characterized in that: The compound is selected from the following compounds: .

2. A method for preparing the compound according to claim 1, characterized in that: The following steps are involved: (1) Extraction and separation: crush the red euphorbia, extract with ethanol as solvent, filter to obtain the extract, and concentrate to obtain the extract; dissolve the extract in water, extract with ethyl acetate, separate the aqueous solution by macroporous adsorption resin column chromatography, and then separate by MCI column chromatography to obtain the target compound-containing parts KVB, KVC, KVD and KVE; in the extraction method, the ethanol concentration is 90%, and the extraction temperature is room temperature; in the macroporous adsorption resin column chromatography method, the mobile phase is ethanol / water; in the MCI column chromatography method, the stationary phase is MCI gelCHP20p, and the mobile phase is methanol / water; (2) Purification: The target compound-containing fractions KVB, KVC, KVD and KVE obtained in step (1) are first purified by preparative HPLC and then by semi-preparative HPLC to obtain target compounds KV-1 to KV-9; in the HPLC method, the stationary phase of the chromatographic column is ODS; in the preparative HPLC method, the mobile phase is 40% to 80% methanol / water; in the semi-preparative HPLC method, the mobile phase is 30% to 50% acetonitrile / water or 45% to 65% methanol / water.

3. Use of the compound according to claim 1 in the preparation of a PTP1B inhibitor.

4. Use of the compound according to claim 1 in the preparation of a selective PTP1B inhibitor.

5. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating type 2 diabetes by inhibiting PTP1B.

6. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and / or treating obesity by inhibiting PTP1B.